Report Overview

According to the deep-dive market assessment study conducted by Growth+ Reports, the Global Advanced Parenteral Drug Delivery Devices Market was pegged at US$ 3.48 billion in 2021. The market is expected to witness a CAGR of 4.1% from 2022 to 2030. 

Market Fundamentals

Parenteral drugs are a class of medications that are administered parenterally i.e., typically by injecting the medication directly into the patient's body either through intravenous, intramuscular, Intrathecal, or subcutaneous routes. They are absorbed directly into the bloodstream and provided with targeted drug delivery system. Parenteral drugs have a faster onset of action because they do not go through the liver. 

[7564545]

Market Dynamics

Technology advancements in parenteral drug delivery have led to the development of novel devices that allow for advanced drug targeting and sustained release of medication thereby increasing the overall demand for the advanced parenteral drug delivery devices market. Moreover, the numerous improvements being made in biologics, like monoclonal antibodies, next-generation cell, and gene therapies, are also driving the growth of advance parenteral drug delivery devices market. Additionally, the rising number of approval and launch of biosimilars is further expected to propel the growth of the market in forecast period. The increased use of patient-specific dosage or precision medicine, which is required to achieve optimal drug levels can be administered via parenteral devices thus increasing the demand for prenatal devices. The increased demand for self-administered medications, as well as the rising prevalence of cardiovascular diseases, diabetes, and cancer, and the increasing investment in research and development with rise in number of clinical trials are also some of the driving factors. The increased use of patient-specific dosage or precision medicine, which is required to achieve optimal drug levels that can be administered via parenteral devices. For market growth. However, stringent regulations for the approval of advance parenteral drug delivery devices is hindering the market growth along with, complications associated with parenteral drugs, such as risk of infection, lack of drug reversal, and risk of hypersensitivity are restraining factors in addition with high cost, human error during administration, and packaging errors.

Market Ecosystem

The global advance parenteral drug delivery devices market is analyzed from three perspectives: application, products, and region.

Advanced Parenteral Drug Delivery Devices Market by Application 

Based on application the advance parenteral drug delivery devices is segmented into endocrine agents, cardiovascular agents, respiratory agents, gastrointestinal agents, central nervous system agents, nutritional agents, and anti-infective agents. The endocrine agents dominated the market in 2021. The larger share of the segment can be attributed to the increasing prevalence of endocrinal disorders worldwide which includes diabetes, thyroid disorders (hyperthyroidism and hypothyroidism). Diabetes has the highest prevalence rate compared to other endocrinal disorders. Moreover, unhealthy lifestyle and rise in obese population is also playing a pivotal role in the growth of the segment.  

Advanced Parenteral Drug Delivery Devices Market by Products

[32435435]

Based on products the advance parenteral drugs delivery devices market is segmented into IV catheters, injector cartridges, prefilled syringes, and hypodermic syringes. The prefilled syringes market held the largest market share in 2021. This large share can be attributed to the accurate prefilled dosage, increased safety, ease of administration for patients and healthcare professionals, less risk of needle contamination, and lower chance of infection.

Advanced Parenteral Drug Delivery Devices Market by Region 

Based on region, the global advance parenteral drugs delivery devices market has been segmented into North America, Europe, Asia Pacific, and the rest of the World. North America held largest market share of the advance parenteral drugs delivery devices market in 2021. Asia Pacific is the fastest growing regional market. The North America's significant market share can be largely attributed to the technologically developed infrastructure for health care and qualified staff. Additionally increased demand for self-administration of drugs with rapid innovation in development of biologics and generic (biosimilars) injectable. Moreover, rise in the chronic diseases like cancer, cardiovascular diseases, and diabetes, according to Centers for Disease Control and Prevention (CDC) 11.3% of U.S. population have diabetes which accumulates 37.3 million people, heart diseases are the leading cause of death in U.S.  about 697,000 people died in 2020.  Presence of top players in the region is also contributing to the growth of the regional market.

Competitive Landscape

Some of the prominent players operating in the global advance parenteral drugs delivery devices market are:

• AstraZeneca Plc
• Abbott Laboratories
• Amgen, Inc.
• Baxter International, Inc.
• Becton, Dickinson and Company
• Bristol-Myers Squibb Company
• AptarGroup, Inc.
• Novartis AG
• Pfizer, Inc.
• GlaxoSmithKline Plc
• F. Hoffmann-La Roche AG

Strategic Developments

• In May 2022, Lubrizol Life Sciences has launched Apisolex a novel solubility-enhancing excipient for use in parenteral drug products. It improves the solubility and help high drug loading. It helps to streamline the manufacturing process and lower the API loss.
• In November 2021, Fyarro, Aadi Bioscience, Inc. got FDA approval for sirolimus protein-bound particles for injectable suspension for adult’s patients suffering from locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.

Frequently Asked Questions About This Report